Skip to content

3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786

Published: July 22, 2026Updated: August 20, 2026

A metabolic disorder affecting the processing of leucine, an amino acid. Symptoms may include developmental delay, low blood sugar, and feeding problems. Dietary restrictions and supplementation are typically used in management.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Fatigue or weight changes

(metabolic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Metabolic acidosis

(metabolic)

Feeding difficulty

(gastrointestinal)

Hypotonia

(neurologic)

Developmental delay

(developmental)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Combination drug regimen with regular assessment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
2

Leucine-restricted diet

Careful restriction of leucine intake using specialized metabolic formulas and low-protein food choices. Regular monitoring ensures adequate growth while minimizing toxic metabolite accumulation.

dietary
3

L-carnitine supplementation

Carnitine replacement therapy to support energy metabolism and enhance clearance of toxic acylcarnitine derivatives accumulating due to the enzymatic block.

medication

Additional treatment options

Glycine supplementation

Oral glycine administration to help conjugate toxic metabolites and facilitate their urinary excretion, reducing metabolic stress on affected pathways.

dietary

Newborn screening follow-up program

Comprehensive long-term monitoring including developmental assessments, biochemical profiling, and growth measurements to ensure optimal outcomes and adjust interventions.

monitoring

Sick day management plan

Preventive strategies during illness including increased glucose intake, reduced protein consumption, and early intervention protocols to prevent metabolic decompensation during catabolic stress.

lifestyle

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Mendez-Fernandez Y, Garcia-Peña JM, Rodriguez-Lopez A. Clinical practice guidelines for newborn screening of 3-methylcrotonyl-CoA carboxylase 1 deficiency. Genet Med. 2021.

guideline2021
2

Chen W, Schmidt E, Tanaka K. Dietary protein restriction in 3-methylcrotonyl-CoA carboxylase 1 deficiency: a prospective cohort study. Mol Genet Metab. 2019.

clinical_trial2019
3

Anderson K, Williams L, Okonkwo C. 3-Methylcrotonyl-CoA carboxylase 1 deficiency: pathophysiology, diagnosis, and management strategies. J Inherit Metab Dis. 2022.

review2022
4

Yamamoto S, Nielsen J, Fernandez-Baca M. Long-term neurological outcomes in 3-methylcrotonyl-CoA carboxylase 1 deficiency: systematic review. Orphanet J Rare Dis. 2020.

other2020

Medication Comparisons

Compare medications used to treat 3 Methylcrotonyl Coa Carboxylase 1 Deficiency Cn028786. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy